Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Chimerism for 20q11.2 microdeletion of GDF5 explains discordant phenotypes in monochorionic-diamniotic twins.

Meredith MM, Crabb B, Vargas M, Hirsch BA.

Am J Med Genet A. 2017 Dec;173(12):3182-3188. doi: 10.1002/ajmg.a.38463. Epub 2017 Sep 8.

PMID:
28884893
2.

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531.

Voigt AP, Brodersen LE, Alonzo TA, Gerbing RB, Menssen AJ, Wilson ER, Kahwash S, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Loken MR.

Haematologica. 2017 Dec;102(12):2058-2068. doi: 10.3324/haematol.2017.169029. Epub 2017 Sep 7.

3.

Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.

Kutny MA, Alonzo TA, Gerbing RB, Wang YC, Raimondi SC, Hirsch BA, Fu CH, Meshinchi S, Gamis AS, Feusner JH, Gregory JJ Jr.

J Clin Oncol. 2017 Sep 10;35(26):3021-3029. doi: 10.1200/JCO.2016.71.6183. Epub 2017 Aug 2.

PMID:
28767288
4.

Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.

Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS.

Blood. 2017 Aug 17;130(7):943-945. doi: 10.1182/blood-2017-01-762336. Epub 2017 Jul 3. No abstract available.

PMID:
28674028
5.

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S.

J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23.

PMID:
28644774
6.

Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash SB, McKenney A, Kolb EA, Gamis AS, Meshinchi S.

Clin Cancer Res. 2017 Jul 15;23(14):3649-3656. doi: 10.1158/1078-0432.CCR-16-2353. Epub 2017 Jan 20.

PMID:
28108543
7.

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

J Hematol Oncol. 2016 Nov 30;9(1):133. No abstract available.

8.

miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.

Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, Meshinchi S.

Pediatr Blood Cancer. 2016 Dec;63(12):2096-2103. doi: 10.1002/pbc.26157. Epub 2016 Aug 11.

9.

Historical perspectives of The American Association for Thoracic Surgery: Bruce W. Lytle, MD.

Davies SW, Hirsch BA, Lau CL; AATS Centennial Committee.

J Thorac Cardiovasc Surg. 2016 Sep;152(3):651-4. doi: 10.1016/j.jtcvs.2016.06.020. Epub 2016 Jun 25. No abstract available.

PMID:
27530634
10.

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.

Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S.

J Clin Oncol. 2016 Mar 1;34(7):747-55. doi: 10.1200/JCO.2015.62.6846. Epub 2016 Jan 19.

11.

Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes.

Poynter JN, Richardson M, Blair CK, Roesler MA, Hirsch BA, Nguyen P, Cioc A, Warlick E, Cerhan JR, Ross JA.

Cancer Epidemiol. 2016 Feb;40:134-40. doi: 10.1016/j.canep.2015.12.005. Epub 2015 Dec 22.

12.

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S.

Clin Cancer Res. 2016 Apr 15;22(8):1951-7. doi: 10.1158/1078-0432.CCR-15-1349. Epub 2015 Dec 7.

13.

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

J Hematol Oncol. 2015 Oct 20;8:115. doi: 10.1186/s13045-015-0215-4. Erratum in: J Hematol Oncol. 2016 Nov 30;9(1):133.

14.

Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group.

Kutny MA, Alonzo TA, Gamazon ER, Gerbing RB, Geraghty D, Lange B, Heerema NA, Sung L, Aplenc R, Franklin J, Raimondi SC, Hirsch BA, Konkashbaev A, Cox NJ, Onel K, Gamis AS, Meshinchi S.

Leukemia. 2015 Dec;29(12):2424-6. doi: 10.1038/leu.2015.171. Epub 2015 Jul 1. No abstract available.

15.

Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

Clin Cancer Res. 2015 Jul 15;21(14):3187-95. doi: 10.1158/1078-0432.CCR-14-2684. Epub 2015 Mar 30.

16.

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.

Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S.

Blood. 2014 Oct 9;124(15):2400-7. doi: 10.1182/blood-2014-04-570929. Epub 2014 Aug 21.

17.

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R.

J Clin Oncol. 2014 Sep 20;32(27):3021-32.

18.

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.

Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, Meshinchi S.

Br J Haematol. 2014 Jul;166(2):254-259. doi: 10.1111/bjh.12852. Epub 2014 Mar 25.

19.

High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

Leuk Lymphoma. 2014 Dec;55(12):2817-21. doi: 10.3109/10428194.2014.893305. Epub 2014 Mar 24.

20.

BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S.

Pediatr Blood Cancer. 2014 Apr;61(4):647-52. doi: 10.1002/pbc.24822. Epub 2013 Oct 11.

Supplemental Content

Loading ...
Support Center